Form 4: Ultragenyx EVP Crombez Sells Shares to Cover Tax Obligations

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 142 shares of common stock on April 18, 2024, to cover tax withholdings related to vesting RSUs.

Summary

• On April 18, 2024, Eric Crombez, the EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 142 shares of the company's common stock.
• The sale was executed at a price of $44.1 per share.
• This transaction was conducted to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Crombez still beneficially owns 48,785 shares of Ultragenyx common stock, including shares underlying RSUs subject to vesting conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, with no indication of a change in the executive's long-term confidence in the company.

Industry Context

Sales of shares by company executives are a common occurrence, often related to compensation and tax obligations. It's important to consider the size of the sale relative to the executive's total holdings. This sale appears to be related to tax obligations from vesting RSUs, which is a normal part of executive compensation.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the context of tax obligations.

Key Dates